RT Journal Article
SR Electronic
T1 Secondary infections modify the overall course of hospitalized COVID-19 patients: A retrospective study from a network of hospitals across North India
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.27.21264070
DO 10.1101/2021.09.27.21264070
A1 Budhiraja, Sandeep
A1 Tarai, Bansidhar
A1 Jain, Dinesh
A1 Aggarwal, Mona
A1 Indrayan, Abhaya
A1 Das, Poonam
A1 Mishra, RS
A1 Bali, Supriya
A1 Mahajan, Monica
A1 Kirtani, Jay
A1 Tickoo, Rommel
A1 Soni, Pankaj
A1 Nangia, Vivek
A1 Lall, Ajay
A1 Kishore, Nevin
A1 Jain, Ashish
A1 Singh, Omender
A1 Singh, Namrita
A1 Kumar, Ashok
A1 Saxena, Prashant
A1 Dewan, Arun
A1 Aggarwal, Ritesh
A1 Mehra, Mukesh
A1 Jain, Meenakshi
A1 Nakra, Vimal
A1 Sharma, B D
A1 Pandey, Praveen Kumar
A1 Singh, YP
A1 Arora, Vijay
A1 Jain, Suchitra
A1 Chhabra, Ranjana
A1 Tuli, Preeti
A1 Boobna, Vandana
A1 Joshi, Alok
A1 Aggarwal, Manoj
A1 Gupta, Rajiv
A1 Aneja, Pankaj
A1 Dhall, Sanjay
A1 Arora, Vineet
A1 Chugh, Inder Mohan
A1 Garg, Sandeep
A1 Mittal, Vikas
A1 Gupta, Ajay
A1 Jyoti, Bikram
A1 Sharma, Puneet
A1 Bhasin, Pooja
A1 Jain, Shakti
A1 Singhal, RK
A1 Bhasin, Atul
A1 Vardani, Anil
A1 Pal, Vivek
A1 Pande, Deepak Gargi
A1 Gulati, Tribhuvan
A1 Nayar, Sandeep
A1 Kalra, Sunny
A1 Garg, Manish
A1 Pande, Rajesh
A1 Bag, Pradyut
A1 Gupta, Arpit
A1 Sharma, Jitin
A1 Handoo, Anil
A1 Burman, Purabi
A1 Gupta, Ajay Kumar
A1 Choudhary, Pankaj Nand
A1 Gupta, Ashish
A1 Gupta, Puneet
A1 Joshi, Sharad
A1 Tayal, Nitesh
A1 Gupta, Manish
A1 Khanna, Anita
A1 Kishore, Sachin
A1 Sahay, Shailesh
A1 Dang, Rajiv
A1 Mishra, Neelima
A1 Sekhri, Sunil
A1 Srivastava, Rajneesh Chandra
A1 Agrawal, Mitali Bharat
A1 Mathur, Mohit
A1 Banwari, Akash
A1 Khetarpal, Sumit
A1 Pandove, Sachin
A1 Bhasin, Deepak
A1 Singh, Harpal
A1 Midha, Devender
A1 Bhutani, Anjali
A1 Kaur, Manpreet
A1 Singh, Amarjit
A1 Sharma, Shalini
A1 Singla, Komal
A1 Gupta, Pooja
A1 Sagar, Vinay
A1 Dixit, Ambrish
A1 Bajpai, Rashmi
A1 Chachra, Vaibhav
A1 Tyagi, Puneet
A1 Saxena, Sanjay
A1 Uniyal, Bhupesh
A1 Belwal, Shantanu
A1 Aier, Imliwati
A1 Singhal, Mini
A1 Khaduri, Ankit
YR 2021
UL http://medrxiv.org/content/early/2021/09/29/2021.09.27.21264070.abstract
AB Introduction SARS-CoV-2 infection increases the risk of secondary bacterial and fungal infections and contributes to adverse outcomes. The present study was undertaken to get better insights into the extent of secondary bacterial and fungal infections in Indian hospitalized patients and to assess how these alter the course of COVID-19 so that the control measures can be suggested.Methods This is a retrospective, multicentre study where data of all RT-PCR positive COVID-19 patients was accessed from Electronic Health Records (EHR) of a network of 10 hospitals across 5 North Indian states, admitted during the period from March 2020 to July 2021.The data included demographic profile of patients, clinical characteristics, laboratory parameters, treatment modalities, and outcome in those with secondary infections (SIs) and those without SIs. Spectrum of SIS was also studied in detail.Results Of 19852 RT-PCR positive SARS-CO2 patients admitted during the study period, 1940 (9.8%) patients developed SIs. Patients with SIs were 8 years older on average (median age 62.6 years versus 54.3 years; P<0.001) than those without SIs. The risk of SIs was significantly (p < 0.001) associated with age, severity of disease at admission, diabetes, ICU admission, and ventilator use.The most common site of infection was urinary tract infection (UTI) (41.7%), followed by blood stream infection (BSI) (30.8%), sputum/BAL/ET fluid (24.8%), and the least was pus/wound discharge (2.6%). As many as 13.4% had infections with more than organism and 34.1% patients had positive cultures from more than one site. Gram negative bacilli (GNB) were the commonest organisms (63.2%), followed by Gram positive cocci (GPC) (19.6%) and fungus (17.3%). Most of the patients with SIs were on multiple antimicrobials – the most commonly used were the BL-BLI for GNBs (76.9%) followed by carbapenems (57.7%), cephalosporins (53.9%) and antibiotics carbapenem resistant entreobacteriace (47.1%). The usage of emperical antibiotics for GPCs was in 58.9% and of antifungals in 56.9% of cases, and substantially more than the results obtained by culture.The average stay in hospital for patients with SIs was twice than those without SIs (median 13 days versus 7 days). The overall mortality in the group with SIs (40.3%) was more than 8 times of that in those without SIs (4.6%). Only 1.2% of SI patients with mild COVID-19 at presentation died, while 17.5% of those with moderate disease and 58.5% of those with severe COVID-19 died (P< 0.001). The mortality was highest in those with BSI (49.8%), closely followed by those with HAP (47.9%), and then UTI and SSTI (29.4% each). The mortality rate where only one microorganism was identified was 37.8% and rose to 56.3% in those with more than one microorganism. The mortality in cases with only one site of infection was 28.8%, which steeply rose to 62.5% in cases with multiple sites of infection. The mortality in diabetic patients with SIs was 45.2% while in non-diabetics it was 34.3% (p < 0.001).Conclusions Secondary bacterial and fungal infections can complicate the course of almost 10% of COVID-19 hospitalised patients. These patients tend to not only have a much longer stay in hospital, but also a higher requirement for oxygen and ICU care. The mortality in this group rises steeply by as much as 8 times. The group most vulnerable to this complication are those with more severe COVID-19 illness, elderly, and diabetic patients. Varying results in different studies suggest that a region or country specific guideline be developed for appropriate use of antibiotics and antifungals to prevent their overuse in such cases. Judicious empiric use of combination antimicrobials in this set of vulnerable COVID-19 patients can save lives.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding has been included in this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Institutional Ethics Committee, Max Super Speciality Hospital (A unit of Devki Devi Foundation), Address: Service Floor, Office of Ethics Committee, East Block, next to Conference Room, Max Super Speciality Hospital, Saket (A unit of Devki Devi Foundation), 2, Press Enclave Road, Saket, New Delhi 110017 vide ref. no. BHR/RS/MSSH/DDF/SKT-2/IEC/IM/21-24 dated 7th September 2021. The IEC provided no objection and approved the publication of this manuscript.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesdata of all RTPCR positive COVID19 patients was accessed from Electronic Health Records (EHR) of a network of 10 hospitals across 5 North Indian states, admitted during the period from March 2020 to July 2021.